

Government in urging international action on the question of bribery in international business dealings.

(2) That the U.S. Government support the recommendation of the United Nations Group of Eminent Persons (of which you, yourself, Senator, were a member) that the affiliates of transnational corporations should be required to reveal to host governments any sales prohibitions and restrictions in manufacturing imposed by home or other host countries with respect to the health and safety of consumers.

(3) That the U.S. Government, through its representatives to the World Health Organization, support current efforts of that organization to improve its international system of information on drugs and look for ways to restructure the Geneva Research Center for monitoring adverse reactions to drugs so that it may be more suited to the needs of less developed countries.

(4) That the U.S. Government offer, preferably through multilateral channels, financial and technical assistance, independent of any influence from private U.S. firms, for improving the capacity of regulatory agencies in less developed countries to exercise control over the pharmaceutical industry.

(5) Finally, but most important, that the United States redouble the research efforts of its own Government agencies and offer, through multilateral channels, more technical and financial aid to independent, noncommercial research facilities in less developed countries to discover and develop cheaper and better drugs to combat the diseases which afflict and shorten the lives of many millions of our fellow human beings.

Mr. Chairman, these recommendations do not constitute the total solution to the problems I have described earlier, but if they were to be carried out we would have made a good start.

Senator JAVITS. Thank you, Mr. Ledogar. It is very interesting.

Now, it would be simple for me to ask you to identify the Swiss firm to which you refer.

Is there any reason why it should not be identified?

Mr. LEDOGAR. It is identified in my book, Senator.

Senator JAVITS. As what? It is published.

Mr. LEDOGAR. Let me check to be perfectly accurate.

Senator JAVITS. And refer us to the page in your book where it is identified.

Mr. LEDOGAR. It is Ciba-Geigy, on page 17.

Senator JAVITS. Ciba-Geigy?

Mr. LEDOGAR. Yes.

Senator JAVITS. And is there any part of the book you want to put into the record to tell us the story?

Mr. LEDOGAR. I can quote it. It is a single paragraph if you wish. It reads:

Sources within the Brazilian parliament recently called for an investigation into the compromising relationship between multinational pharmaceutical firms and the nation's drug control agencies.

A parliamentary investigating committee was given an initial document of the Swiss firm Ciba-Geigy containing a list of over 135 public officials in the SNFMF [which is the Brazilian regulatory agency] and other licensing agencies who receive small gifts and donations from the company.